Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.

Atom Therapeutics Co., Ltd

Atom Bioscience and Pharmaceutical Co. Ltd.

Changjin Fu

Dongfang Shi

Xi Cheng

Jie Gu

Jianghua Zhu

Pengfei Li

Min Zhang

Weiwei Gong

Yan Yang

Jun Liu

Wenqing Jin

Jie Wu

Jie Wen

A method for synthesizing 3-bromo-5-(2-ethylimidazo[1,2-a] pyridine-3-carbonyl)-2-hydroxybenzonitrile, particularly relates to a method for synthesizing a compound represented by a formula (III), and particularly relates to step A or step B; step A: a compound represented by a formula (I) and a compound represented by a formula (II) are first heated in an organic solvent to react, and the resulting reaction product and a base are heated in the presence of water to continue the reaction to obtain a compound represented by a formula (III); and step B: a compound represented by the formula (I), a compound represented by a formula (II), and a base are heated in an organic solvent to react, and the resulting reaction product is heated in the presence of water to continue the reaction to obtain a compound represented by a formula (III).

Synthesis for 3-bromo-5-(2-ethylimidazo[1, 2-alpha]pyridine-3-carbonyl)-2-hydroxybenzonitrile

Disclosed are a class of URAT1 inhibitor compounds and the use of such compounds. These compounds are compounds represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on hURAT1-transported uric acid in HEK293 transfected cells, and show that such compounds have a good potential for application in the treatment of hyperuricemia or gout.

URAT1 inhibitor and use thereof

The invention discloses compounds for treatment or prevention of liver diseases. The compounds are compounds represented by a formula (I) or (II), optical isomers or pharmaceutically acceptable salts of the compounds. The compounds and optical isomers or pharmaceutically acceptable salts of the compounds can be applied to preparation of drugs for treatment or prevention of liver diseases.

Compound for treatment or prevention of liver diseases

The invention discloses a class of compounds for treating or preventing hyperuricemia or gout, which is a compound shown in general formula (I) or a pharmaceutically acceptable salt. These compounds and their pharmaceutically acceptable salts in the invention are useful for the promotion of uric acid excretion to treat or prevent hyperuricemia or gout.

Compound for treating or preventing hyperuricemia or gout

It discloses compounds for the treatment and prevention of breast cancer, which are specifically 2-phenyl benzoselenazole compounds, pharmaceutically acceptable salts thereof and prodrugs thereof. The present invention further discloses pharmaceutical compositions containing the compounds and applications of the compounds in preparing medicines for the treatment and prevention of breast cancer in mammals. The compounds of the present invention can effectively inhibit or reduce the growth or proliferation of breast cancer cells in mammals, with no inhibition effect on the growth of part of the tested cell lines except for the breast cancer cell lines, and are highly selective.

Compounds for the treatment or prevention of breast cancer

A 2-aryl selenazole compound and a pharmaceutical composition are disclosed, wherein the 2-aryl selenazole compound is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The 2-aryl selenazole compound has the activity of inhibiting xanthine oxidase. The compound or a pharmaceutically acceptable salt thereof can be applied in terms of preparing a drug used for prevention or treatment of hyperuricemia, gout, diabetic nephropathy, an inflammatory disease or a neurological disease.

Growing community of inventors

Zhenjiang, China

Changjin Fu